logo
CDC investigating hospitalizations of five people who recently received chikungunya vaccine

CDC investigating hospitalizations of five people who recently received chikungunya vaccine

CNN27-02-2025

The US Centers for Disease Control and Prevention is currently investigating five hospitalizations that occurred in people who had recently received a vaccine that prevents disease caused by the chikungunya virus.
In a notice posted Tuesday on a vaccine information page for health-care providers, the CDC said that the people, all 65 and older, were hospitalized for cardiac or neurologic events following vaccination with IXCHIQ, the only chikungunya vaccine currently licensed in the United States.
CNN has reached out to the CDC for comment.
Chikungunya virus is typically spread to people through the bite of an infected mosquito. Most adults don't receive the vaccine; it is sometimes recommended for certain travelers at an increased risk of being exposed to the mosquito-borne disease.
'This topic will be discussed at an upcoming meeting of the Advisory Committee on Immunization Practices (ACIP). Healthcare providers should discuss the benefits and risks of vaccination with individual travelers based on their age, destination, trip duration, and planned activities,' the CDC's online notice said in part.
The chikungunya vaccine and surveillance for adverse events originally were scheduled to be discussed in an ACIP meeting Wednesday, according to a draft meeting agenda, but that meeting has been postponed.
Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center and ACIP liaison, said the CDC investigation is an example of the agency's vaccine surveillance system 'working excellently and sending out a signal' in detecting rare events that might deserve further investigation.
'And of course, the CDC and the local people who are taking care of these patients are working on that now, which is entirely appropriate. That's the way the system is supposed to work,' Schaffner said.
'Remember, we're still trying to work out whether this is a causal relationship or a coincidental one,' he said about the investigation, in which he is not directly involved. 'Let's not draw any conclusions yet. That's why they're doing the investigation.'
The IXCHIQ vaccine, administered as a single-dose shot into the muscle, contains a live, weakened version of the chikungunya virus. The vaccine, manufactured by the biotechnology company Valneva, was the first vaccine approved by the US Food and Drug Administration to prevent disease caused by chikungunya virus. The approval, in November 2023, was for people 18 and older who are at increased risk of exposure to chikungunya virus.
'It's recommended in a very restricted way to travelers who are going to countries where there is a current outbreak of chikungunya virus infection, and also to travelers who are going to countries who had experienced an outbreak within the past five years,' Schaffner said. 'And also to laboratorians who work with the chikungunya virus in the laboratory.'
CNN has reached out to Valneva for comment. Prescribing information for the vaccine states, 'Vaccination with IXCHIQ may cause severe or prolonged chikungunya-like adverse reactions.'
Chikungunya virus circulates in tropical and subtropical regions. In the United States, locally acquired infections have not been reported since 2019, according to the CDC. But cases and outbreaks had been identified in more than 100 countries in the Americas, Africa, Asia, Europe, and the Indian and Pacific Oceans.
Symptoms of chikungunya infections include fever, joint pain, headache, muscle pain, joint swelling or rash, according to the CDC, and the best way to prevent chikungunya is to avoid mosquito bites. There are currently no medications to treat chikungunya, but infected people may feel better with rest, fluids and over-the-counter medications for pain and fever.
In Tuesday's notice, the CDC said that common adverse reactions following vaccination that occurred in more than 10% of vaccinated people in clinical trials included tenderness, headache, fatigue, muscle pain, joint pain, fever and nausea. In some people, 'severe or prolonged chikungunya-like adverse reactions' occurred.
Chikungunya-like reactions included 'fever, joint pain, headache, rash, and can also include cardiac and neurologic conditions which were serious in two cases,' Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, who was not involved in the clinical studies, said in an email Wednesday.
The CDC's notice encouraged health-care providers 'to report all adverse events that might be caused by vaccination to the CDC/FDA Vaccine Adverse Events Reporting System (VAERS),' by submitting a report online or using a PDF form.
'The robust vaccine safety surveillance system often identifies extremely rare adverse effects of vaccines after approval,' said Barouch, an infectious disease expert not involved in the CDC investigation.
When the vaccine was approved in 2023, the FDA noted that its safety was evaluated in two clinical studies conducted in North America in which about 3,500 adults received a dose of the vaccine, with one study including about 1,000 participants who received a placebo. Severe chikungunya-like adverse reactions occurred in 1.6% of IXCHIQ recipients and none of the placebo recipients, according to the FDA.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CDC backtracks on layoffs, rehires more than 400 people
CDC backtracks on layoffs, rehires more than 400 people

Yahoo

time30 minutes ago

  • Yahoo

CDC backtracks on layoffs, rehires more than 400 people

The Centers for Disease Control and Prevention is reinstating more than 400 people who had received layoff notices, according to an email from CDC leadership to employees seen by POLITICO. The rehiring, announced internally today, marks the largest number of employees that the agency has asked back to date. Around half of those employees are in the National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention, and around a third are in the National Center for Environmental Health. Other divisions seeing reinstatements include the National Center for Health Statistics, Center for Forecasting and Outbreak Analytics, Office of Human Resources, Global Health Center, Office of Acquisition Services and Office of Communications. HHS spokesperson Andrew Nixon did not immediately respond to a request for comment. He told Fox News, which first reported the news: 'The Trump Administration is committed to protecting essential services — whether it's supporting coal miners and firefighters through [the National Institute for Occupational Safety and Health], safeguarding public health through lead prevention, or researching and tracking the most prevalent communicable diseases.' — Key context: In April, roughly 2,400 CDC employees received termination notices amid a massive reorganization of the Department of Health and Human Services. But the agency has periodically rehired staff over the past few months.

What to know about the new ‘Nimbus' COVID variant
What to know about the new ‘Nimbus' COVID variant

The Hill

time37 minutes ago

  • The Hill

What to know about the new ‘Nimbus' COVID variant

The World Health Organization is keeping an eye on a new COVID-19 variant called NB.1.8.1, or 'Nimbus,' that has spread across Europe, the Americas and the Western Pacific. Nimbus is a descendant of the Omicron variant of the virus and was first identified in late January. Its spike mutations appear to make it more transmissible than other COVID variants, according to the WHO. Spike mutations refer to changes in spike proteins, which sit on the surface of the virus and help it enter healthy cells. While it is spreading in the U.S. and Canada, along with 20 other countries, it does not appear to be driving an increase in sickness or hospitalization. In April, NB.1.8.1 sequences made up 10.7 percent of all submitted sequences from confirmed COVID infections, up from 2.5 percent a month earlier, according to a risk evaluation released by the WHO. The WHO last month deemed NB.1.8.1 a variant 'under monitoring.' Here's what to know about the variant. Most cases of COVID-19 in the U.S. still stem from the LP.8.1 strain, another Omicron descendant. But it looks like NB.1.8.1 might soon replace it as the more common strain, according to data from the Centers for Disease Control and Prevention (CDC). The CDC estimates that 37 percent of COVID-19 cases in the U.S. stem from the NB.1.8.1 variant while 38 percent are a result from an infection of the LP.8.1 strain of the disease. At the end of May, the agency estimated that the NB.1.8.1 variant caused about 15 percent of all COVID cases. But the agency notes on its website that due to low numbers of virus sequences being reported, precision in the most recent reporting period is low. The NB.1.8.1 variant has been found in at least 13 states, according to Today, which cited data from the Global Initiative on Sharing All Influenza Data (GISAID) database. Those states are: California, New York, New Jersey, Maryland, Arizona, Illinois, Hawaii, Massachusetts, Ohio, Rhode Island, Vermont, Virginia and Washington. The available data on 'Nimbus' suggests that it poses a low global threat and that existing COVID-19 vaccines provide adequate protection against severe illness and hospitalization, according to the WHO. 'Currently approved COVID-19 vaccines are expected to remain effective to this variant against symptomatic and severe disease,' reads the WHO's risk evaluation. 'Despite a concurrent increase in cases and hospitalizations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation.' Lionel Gesh, an international consultant at the WHO, told The Hill that many new cases in Canada are likely linked to the NB.1.8.1 variant, but that there has not been any major changes in the country in terms of cases, hospitalizations, ICU admissions or deaths linked to COVID-19. Symptoms of NB.1.8.1 seem to be similar to those associated with other Omicron variants, according to Gresh. Some common COVID-19 symptoms include cough, fever, fatigue, muscle aches, congestion, headache, nausea, vomiting, and a new loss of smell or taste, according to the CDC. 'We should be as concerned about [NB.1.8.1] as we are concerned for COVID in general,' Gesh said. 'Not more, not less.' Some recent COVID-19 patients have reported experiencing something called 'razor blade throat,' according to Salon. But it is unclear if that symptom is connected to one of the COVID variants or another respiratory illness circulating, Ryan Gregory, an evolutionary and genome biologist at the University of Guelph in Canada, told the outlet.

Unpacking RFK's lengthy social media post after firing vaccine committee members
Unpacking RFK's lengthy social media post after firing vaccine committee members

USA Today

time39 minutes ago

  • USA Today

Unpacking RFK's lengthy social media post after firing vaccine committee members

Unpacking RFK's lengthy social media post after firing vaccine committee members Show Caption Hide Caption RFK Jr. expels entire CDC vaccine advisory committee Health Secretary Robert Kennedy Jr. removed a 17-member panel at the Centers for Disease Control and Prevention that issues recommendations on vaccines. unbranded - Newsworthy A day after abruptly firing the entire committee that advises the federal government on vaccine safety, Health and Human Services Secretary Robert F. Kennedy Jr. said he would reconstitute it with 'highly credentialed physicians and scientists' amid backlash from his detractors about the terminations. In a long post on X on June 10, Kennedy criticized the process by which the Advisory Committee for Immunization Practices recommends new vaccines, implying that "adequate safety trials" were not being conducted before recommending new vaccines to children, a notion that was strongly disputed by vaccine experts. Kennedy, who has a long record of promoting anti-vaccine views, also said the new Advisory Committee for Immunization Practices will have no 'ideological anti-vaxxers' but that the committee will apply 'evidence-based decision-making with objectivity and common sense.' 'The most outrageous example of ACIP's malevolent malpractice has been its stubborn unwillingness to demand adequate safety trials before recommending new vaccines for our children,' he wrote. Kennedy said a compliant American child receives more shots now from conception to 18 years of age compared to 1986, none of which required placebo-controlled trials. That was the year when the Vaccine Injury Compensation Program was set up, protecting vaccine makers from liability and establishing a federal program to compensate individuals injured by certain vaccines. 'This means that no one can scientifically ascertain whether these products are averting more problems than they are causing,' he wrote. A placebo-controlled study is a type of clinical trial where one group of participants receives an active treatment, while another group receives an inactive substance, helping researchers to determine whether the active treatment is truly effective. But conducting placebo-controlled studies on vaccines that are improvements on existing vaccines presents ethical and practical challenges, say vaccine experts. 'If a vaccine for a serious disease (e.g., measles, polio) already exists and is proven effective, giving participants a placebo instead of the vaccine could expose them to preventable harm or death,' wrote Dr. Jerome Adams, the former U.S. Surgeon General under President Trump's first term, in a June 9 post on X. How do vaccines work? Medical experts explain. New vaccines always undergo a placebo-controlled study, said Dr. Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia and a member of the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee. But Kennedy's definition of placebo is different from FDA's, said Offit. Kennedy has sought to narrowly define placebos as salt water, said Offit, while the FDA defines it as an 'inactive substance.' 'A placebo may contain sodium sulfate or potassium sulfate or may contain sucrose, or it may contain an emulsifier – those are all generally regarded as safe,' said Offit. 'He doesn't regard them as safe.' HHS did not respond to USA TODAY seeking a comment on how Kennedy's definition differs from that of the FDA. Offit said Kennedy is a lawyer who has spent years suing pharmaceutical companies, and 'his job is to scare people about vaccines ultimately, so he can bring them back to court and sue companies,' he said. Meanwhile, in his announcement of the removal of the 17 members of the ACIP committee Kennedy said the purpose was to insulate the committee from 'conflicts of interest.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store